4 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
New tools for monitoring drug resistance and treatment response in visceral leishmaniasis in the Indian subcontinent (KALADRUG-R)
Date du début: 1 nov. 2008, Date de fin: 30 avr. 2013,
...isceral leishmaniasis (VL), one of the most-neglected infectious diseases, has an annual incidence of 500,000 cases. Early treatment is a major pillar of the current program for VL elimination on the Indian sub-continent. However, the arsenal of available drugs is very limited, and their use is jeopardized by drug resistance. Combination regimens for VL are under clinical development, but it will ...
Voir le projet
10
Participants partenaires
TERMINÉ
Signalling in life cycle stages of malaria parasites (MALSIG)
Date du début: 1 févr. 2009, Date de fin: 31 juil. 2012,
...ynamics (trafficking, transporters) Approaches will include proteomics, reverse genetics, structural biology, and the use of animal models of malaria. The consortium is constituted of EU and Indian partners with a proven track record either in research into one of the developmental stages/processes described above, or in signal transduction in malaria parasites. The project will significantly st ...
Voir le projet
18
Participants partenaires
TERMINÉ
"PRe-clinicAl studies of a PSA-based human vaccine candidate targeting visceral, cutaneOus and mucocutaneous Leishmaniasis and Development of the associated procedures for further clinical trials" (RAPSODI)
Date du début: 1 janv. 2009, Date de fin: 30 juin 2012,
"The global aim of RAPSODI is : · to develop a human vaccine candidate against most or all Leishmania species that cause the most severe leishmaniasis in the world. An unique vaccinal solution will thus be provided to protect against the various clinical phenotypes (namely visceral, cutaneous and mucocutaneaous leishmaniasis, VL, CL and ML respectively). · to establish all the associated procedure ...
Voir le projet
9
Participants partenaires
TERMINÉ
Development of a DNA vaccine for visceral leishmaniasis (LEISHDNAVAX)
Date du début: 1 janv. 2009, Date de fin: 30 juin 2012,
"This project will focus on the preclinical development of a DNA vaccine for human visceral leishmaniasis. The project is based upon the DNA vaccine technology and immunomodulators developed at Mologen AG (Berlin, Germany), which are in clinical development for cancer and 3-5 known antigens that already have demonstrated profiles of protection in animal models of leishmaniasis. Antigens will be se ...
Voir le projet